Renal, metabolic and cardiovascular considerations of SGLT2 inhibition (Q39035951)

8 September 2017

1 reference

title

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition (English)

1 reference

8 September 2017

1 reference

1

Ralph A DeFronzo

1 reference

8 September 2017

Luke Norton

2

1 reference

8 September 2017

Muhammad Abdul-Ghani

series ordinal

3

1 reference

8 September 2017

language of work or name

English

0 references

publication date

12 December 2016

1 reference

Nature Reviews Nephrology

8 September 2017

1 reference

8 September 2017

13

1 reference

8 September 2017

1

1 reference

8 September 2017

11-26

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2016.170

8 September 2017

0 references

cites work

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

10-year follow-up of intensive glucose control in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Effects of intensive glucose lowering in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Images in clinical medicine. Paget's disease of the mandible

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Glucose control and vascular complications in veterans with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Renal glucose production and utilization: new aspects in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Biology of human sodium glucose transporters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Maximum Tubular Reabsorption Capacity for Glucose and Renal Hemodynamics during Rapid Hypertonic Glucose Infusion in Normal and Diabetic Subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Systemic hypertension in diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Improved glycemic control in mice lacking Sglt1 and Sglt2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Sotagliflozin as a potential treatment for type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Dapagliflozin lowers plasma glucose concentration and improves β-cell function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Role of free fatty acids and insulin in determining free fatty acid and lipid oxidation in man.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Uric acid and cardiovascular risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Glomerular hyperfiltration and renal disease progression in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Glomerular hemodynamics in experimental diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Association of Cardiometabolic Multimorbidity With Mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

The theoretical bases of indirect calorimetry: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Ketone body metabolism and cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

EMPA-REG – the “diuretic hypothesis”

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Low-dose intravenous glucagon has no effect on myocardial contractility in normal man. An echocardiographic study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2016.170

Intrarenal heterogeneity for fluid, phosphate, and glucose absorption in the rabbit

31 March 2020

1 reference

12 December 2020

Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats

1 reference

12 December 2020

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

12 December 2020

Relationship Between Left Ventricular Structural and Metabolic Remodeling in Type 2 Diabetes.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2016.170

1 reference

Dimensions Publication ID

8 September 2017

1009448867

0 references

Fatcat ID

release_okzrxqk3tjgwxmy6dusufufka4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/okzrxqk3tjgwxmy6dusufufka4

24 November 2022

mapped directly with Wikidata item

1 reference